Metabolic labeling kinetics of brain-derived 24S-hydroxycholesterol in blood in multiple sclerosis: Effects of treatment with the remyelinating antibody rHIgM22

20252 citationsJournal Articlegold Open Access

Authors

Mahalakshmi Shankaran

Kelvin W. Li

Hussein Mohammed · KineMed (United States)

Joan Protasio · KineMed (United States)

Mark Fitch

Marcy Matthews

Edna Nyangau · University of California, Berkeley

Gordon I. Smith

Samuel Klein · Washington University in St. Louis

Abstract

Plasma 24-OHC kinetics provide a minimally invasive biomarker of brain cholesterol metabolism and revealed differences between healthy and clinically stable MS subjects, with increased turnover of the metabolically active 24-OHC pool that normalized in response to rHIgM22 therapy.

Topics & Keywords

Cholesterol and Lipid Metabolism interferon and immune responses RNA Research and Splicing

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Multiple Sclerosis Journal - Experimental Translational and Clinical

Volume 11, Issue 2, pp. 20552173251344555-20552173251344555

DOI: 10.1177/20552173251344555

Field-Weighted Citation Impact: 4.02